Medulloblastoma: time–dose relationship based on a 30-year review

Shielding in whole brain irradiation in the multileaf collimator era: Dosimetric evaluation of coverage using SFOP guidelines against in-house guidelines

“…[1,5,15] In medulloblastoma irrespective of the risk group cranio-spinal irradiation (CSI) with or without chemotherapy is the standard of treatment in postoperative setting. [3,4,[6][7][8][9][10]13,[16][17][18] In such situations, the use of a proper technique for the adequate coverage of PTV is of prime importance.…”

“…In medulloblastoma and ALL, nearly 15-20% of recurrences occur at this site which is attributed to overzealous shielding. [6][7][8][9][10][11][12][13] This emphasizes the importance of a proper technique for designing the shield in cranial radiation. There are various techniques reported in the literature of designing the shield.…”

Prognostic factors in head and neck rhabdomyosarcoma

“…We were not able to include this parameter on multivariate analysis because of the small number of patients. The significance of RT treatment duration has been examined in medulloblastoma and ependymoma, where protracted treatment times were associated with worse local control and survival 9, 10. Whether this is true for group III RMS needs to be further clarified.…”

Comparison of risk of radiogenic second cancer following photon and proton craniospinal irradiation for a pediatric medulloblastoma patient

“…The current standard of care includes surgery and a combination of craniospinal irradiation (CSI) and chemotherapy (Freeman et al , 2002; Gottardo and Gajjar, 2006; Packer et al , 2006; Packer and Vezina, 2008). The long-term survival rate for these patients has improved steadily over the past decades (Miralbell et al , 2002; St Clair et al , 2004; Fossati et al , 2009), a change attributed primarily to postoperative radiation therapy (del Charco et al , 1998). Typically, megavoltage external beam photon therapy (conventional radiotherapy) is used to treat the entire craniospinal axis.…”